~(131)I-血管抑素联合PcDNA-sTRAIL在荷瘤小鼠模型肿瘤靶向治疗的研究

目的构建PcDNA-sTRAIL真核表达载体并进行扩增、纯化,采用131I标记血管抑素(AS)并完成了PcDNA-sTRAIL与131I-AS在荷瘤裸鼠体内的联合抑瘤试验。方法;通过PCR扩增和定向克隆技术成功构建PcDNA-sTRAIL真核表达载体,采用131I标记血管抑素,标记率达85%且体外稳定性好,成功构建了荷瘤裸鼠模型,并进行了荷瘤小鼠联合治疗后SPECT显像和病理结果,完成PcDNA-sTRAIL与131I-AS在荷瘤裸鼠体内的联合抑瘤试验。结果:荷瘤小鼠PcD-NA-sTRAIL与131I-AS联合用药治疗期间肿瘤平均体积较其他单独治疗组增长缓慢。结论:本研究将抑制肿瘤血管生成、促肿瘤细胞凋亡和放射性核素的内照射三重作用相结合并用于抗肿瘤治疗,期望不仅能充分发挥三者的优势,又能为核素内照射与免疫治疗的结合提供有力的实验证据。

A tumor targeted therapy study of PcDNA-sTRAIL combined with 131I-angiostatin on lewis lung garcinoma nude mice

Objective :To build PcDNA-sTRAIL eukaryotic expression vector and amplify,purify it,then observe the joint antitumor effect of the PcDNA-sTRAIL combined with 131I-AS in Lewis Lung Carcinoma nude mice.Methods :Through the PCR amplification and directional cloning technology to build PcDNA-sTRAIL eukaryotic express carrier,use 131I to mark AS.The mark rate could reach 85% and exhibit good in vitro stability.After successfully constructed a tumor-burdened nude mice model,then we got a tumor-burdened mice SPECT imaging.Next,we completed a tumor targeted therapy study of restructuring PcDNA-sTRAIL combined with 131I-AS.Result :The average volume of tumor in the PcDNA-sTRAIL and 131I-AS combined treatment group is smaller the other single treated groups.Conclusion :This research firstly suggested the combined treatment of inhibiting tumor angiogenesis effect,promoting the tumor cell apoptosis effect,and radiation treatment to fight cancer.We expect we could not only take full advantages of the three methods,but also provide powerful experimental evidences for combination treatment of radionuclide and the immune therapy.